MSInsight

MSInsight, a pioneering French health-tech company, is revolutionizing cancer diagnostics by extracting actionable insights from the genome. We are dedicated to creating cutting-edge diagnostic tools for Microsatellite Instability (MSI), a crucial biomarker and predictor of treatment response, particularly for immune checkpoint inhibitors, across multiple cancers.

Our flagship solution, MSIcare, leverages Next-Generation Sequencing (NGS) data to detect MSI with unmatched precision. Clinically validated for colorectal cancer, it surpasses existing tools in analytical performance and will be available as a CE-IVD-certified device to support clinical decision-making.

We welcome collaborations with hospitals to further evaluate and refine our solution.